An Observational Post-Marketing Safety Registry Of Patients Who Have Been Prescribed Sativex
Phase of Trial: Phase IV
Latest Information Update: 13 Oct 2017
Price : $35 *
At a glance
- Drugs Nabiximols (Primary)
- Indications Cancer pain; Diabetic neuropathies; Multiple sclerosis; Muscle spasticity; Neuropathic pain
- Focus Adverse reactions
- Sponsors GW Pharmaceuticals
- 10 Oct 2017 Status changed from recruiting to completed.
- 10 Oct 2015 Final results of patients from the United Kingdom (n=941) presented at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
- 05 Mar 2014 New trial record